Business Context and Reporting Period
CytomX Therapeutics, Inc. filed this Form 8-K on March 17, 2017, to report the entry into a Material Definitive Agreement. The Company, a Delaware corporation, entered into an Amendment to its Collaboration and License Agreement with Bristol-Myers Squibb (BMS) to extend their partnership.
Key Financial Metrics and Transaction Terms
The Amendment grants BMS exclusive worldwide rights to develop and commercialize Probody therapeutics for up to six additional oncology targets and two non-oncology targets. Key financial terms include:
- Upfront Payment: $200,000,000 payable by BMS within 10 days of the effective date.
- Development and Regulatory Milestones (First Modality): Up to $116,000,000 for up to three indications.
- Commercial Milestones (First Modality): Up to $124,000,000 for first commercial sales in various territories.
- Sales Milestones (First Modality): Up to $60,000,000.
- Development and Regulatory Milestones (Second Modality): Up to $56,250,000 for up to three indications.
- Commercial Milestones (Second Modality): Up to $62,000,000 for first commercial sales.
- Sales Milestones (Second Modality): Up to $30,000,000.
- Royalties: Tiered mid-single digit to low double-digit royalties on net sales of commercialized products.
The filing text does not provide specific values for the Company's current revenue, profit, cash flow, margins, debt, or liquidity, as this report focuses on the transaction agreement.
Material Changes and Obligations
Upon receipt of the $200 million upfront payment, CytomX is required to make a payment to The Regents of the University of California (UC) under an existing exclusive license agreement. The Amendment modifies the termination rights of the Original Agreement, allowing BMS to terminate on a target-by-target basis after the second anniversary of the effective date if no regulatory approval has been obtained, subject to advance notice periods.
Guidance, Risks, and Contingencies
- Regulatory Contingency: The closing of the transaction is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act). The effective date is contingent upon the expiration or earlier termination of the HSR waiting period.
- Termination Risks: BMS may terminate the agreement if the medical benefit-to-risk ratio of a product is deemed unfavorable. Either party may terminate for uncured material breach or insolvency.
- Management Commentary: The Company issued a press release on March 20, 2017, announcing the extension of the collaboration to discover Probody therapeutics for cancer and other diseases.
Investor Verification Checklist
- Verify the exact date of HSR Act clearance to confirm the effective date of the $200 million upfront payment.
- Review the specific terms of the payment obligation to The Regents of the University of California to assess net cash impact.
- Confirm the specific six oncology and two non-oncology targets selected by BMS under the Amendment.
- Monitor future Form 10-Q filings for the full text of the Amendment and detailed financial impact.